In the Dark About Uveitis?
It can affect one or both eyes, can occur at any age, can be chronic or last for a short period of time, can be infectious or noninfectious, can occur throughout the eye. It produces swelling and destroys eye tissues. This inflammatory condition can impair vision, cause blindness, and, not surprisingly, adversely affect quality of life. Uveitis is responsible for up to 20% of all blindness, according to the American Uveitis Society,1 yet much remains to be learned about it.
Organizations including the US National Eye Institute are conducting and supporting studies to test new treatment approaches to uveitis and to better understand its causes. When more is known about causes, more can be done toward finding preventive measures.
As these searches for causes and treatments continue, Retina Today is here to help you keep current on the latest findings and guidelines on treatment of uveitis. In this issue’s cover focus, Eric L. Crowell, MD, MPH, and Ashvini K. Reddy, MD, provide a primer on the prevalence and epidemiology of the disease. For patients with suspected uveitis, the use of multimodal, multispectral imaging could lead to early diagnosis and, subsequently, timely treatment. Sunil K. Srivastava, MD, makes the case for use of supplemental ultra-widefield imaging. On the topic of therapeutic treatment options, Andrea Arriola López, MD, MSc, and Thomas Albini, MD, will catch you up on emerging treatments for uveitis.
In the last article in the cover series, Lisa J. Faia, MD, and Kimberly A. Drenser, MD, PhD, take a closer look at the challenges involved in the management of treating pediatric patients with uveitis.
We hope this review and update will help readers keep current on the best diagnostic and treatment trends surrounding this challenging, debilitating disease.
— Karen Roman, Editor-in-Chief
1. American Uveitis Society. www.uveitissociety.org. Accessed September 29, 2017.